tyrosine kinase inhibitor Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1/2 (1)
Unknown (1)

Interventional (1)
Observational (1)

Huiqiang Huang (1)
The First Affiliated Hospital of Zhengzhou University (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadpulmonary function test

I am/have/hadlymphoma

I am/have/hadcreatinine clearance rate

I am/have/hadpulse oximetry

I am/have/hadvegf

I am/have/hadimmunodeficiency

I am/have/hadvascular endothelial growth factor receptor 2

I am/have/hadfollicular lymphoma grade iiib

I am/have/hadanticoagulants

I am/have/hadanticoagulant therapy

I am/have/hadvascular endothelial growth factor

I am/have/hadneutrophil count

I am/have/hadthyroid dysfunction

I am/have/hadmeasurable disease

I am/have/hadpostoperative complication

I am/have/hadliver metastasis

I am/have/hadprothrombin time (pt)

I am/have/hadtubal ligation

I am/have/hadtyrosine

I am/have/hadblood transfusion

added new label for I am/have/had

more

I am looking for

I am looking fortyrosine

I am looking forgranulocyte colony stimulating factor

I am looking foranticoagulants

I am looking forvegf

I am looking forcolony stimulating factor

I am looking fororal contraceptives

I am looking forvascular endothelial growth factor

I am looking forg-csf

I am looking for18f-fdg

I am looking forgrowth factor

I am looking forrituximab

I am looking forapatinib

I am looking forcamrelizumab

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

pulmonary function test

lymphoma

creatinine clearance rate

pulse oximetry

granulocyte colony stimulating factor

0 views
19 Feb, 2024

For Seniors
For adults
Recruiting in 100s
Observational Study
all
Recruiting

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices …

tyrosine

liver metastasis

glioma

vegf

vascular endothelial growth factor

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.